Uso de protocolo de sincronização de estro em receptoras mestiças inovuladas com embriões in vitro

• Ano de defesa: 2010
• Autor(a) principal: Rosado, Marcelo Milagres
• Orientador(a): Guimarães, José Domingos
• Banca de defesa: Espeschit, Claudio José Borela , Torres, Ciro Alexandre Alves , Paula, Tarcízio Antônio Rego de
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal de Viçosa
• Programa de Pós-Graduação: Mestrado em Medicina Veterinária
• Departamento: Biotecnologia, diagnóstico e controle de doenças; Epidemiologia e controle de qualidade de prod. de
• País: BR
• Palavras-chave em Português: Bovinos, Transferência de Embriões, PIV, CIDR
• Palavras-chave em Inglês: Cattle; CIDR®; Embryo transfer; in vitro fertilization
• Área do conhecimento CNPq: CNPQ::CIENCIAS AGRARIAS::MEDICINA VETERINARIA::REPRODUCAO ANIMAL
• Link de acesso: http://locus.ufv.br/handle/123456789/5123

Aiming to study the effect of different estrus synchronization protocols on the pregnancy rate in Bos taurus indicus x Bos taurus taurus recipient cattles, transferred with in vitro produced embryos, this study used 1,933 recipients (3,649 treatments) divided into 6 groups. In the first group, recipients received 2.0 mg of estradiol benzoate (EB) and 500 mg of cloprostenol, in addiction to an intravaginal device (1.9 g of progesterone) that remained for 8 days. Upon withdrawal of the intravaginal device each recipient received a single dose of 0.5 mg of estradiol cypionate (EC), 500 mg of cloprostenol and 400 IU of equine chorionic gonadotropin (eCG). In the second group, recipients received the same treatment as the first group, but without the 500 mg dose of cloprostenol at the placement of the progesterone intravaginal device. In the third group, recipients received at the time of intravaginal progesterone device placement a single dose of 500 mg cloprostenol and 2.0 mg of EB, and the device remained for 9 days. Two days before the intravaginal device removal (day 7) females received a single dose of 500 mg cloprostenol, and at the time of device removal, received a single dose of 0.5 mg of EC and 400 IU of eCG. In the fourth group, the recipients received the same treatment as the third group, but without cloprostenol in the intravaginal progesterone device placement. In the fifth group, recipients received 2.0 mg of EB, and an intravaginal progesterone device that remained for 8 days. Upon withdrawal of the intravaginal device, each recipient received 0.5 mg of EC, 500 mg of cloprostenol and 300 IU of eCG. In the sixth group, recipie nts received 2.0 mg of EB and an intravaginal progesterone device for 9 days. Two days before the withdrawal, (day 7), received 500 mg of cloprostenol and at the time of device removal received 0.5 mg of EC and 300 IU of eCG. All recipients that had corpus luteum were transferred on average 10 days after implant removal, in other words, about 8 days after estrus, and evaluated by ultrasonography 58 days after embryo transfer to pregnancy diagnosis. Data were subjected to descriptive statistics analysis (means, standard deviations and frequency distribution) and qualitative data were arranged in contingency tables and analyzed by chi-square at 5% of probability. Fourth group showed the best recovery rates (84.9%). However, the number of treatments performed (n=86) in group 4 was reduced in comparison with other protocols. Recipients who received Prostaglandin F2&#945; (PGF2&#945;) 48 hours before device removal showed better recovery rates than others and protocol 4 females had better pregnancy rates. The recipients that were in estrus longer than 91 days before device placing had worse recovery rates than recipients in estrus earlier (p<0.05), although did not influence pregnancy rate (p>0.05) . Despite some recipients peculiarities who presented estrus less than 16 days, the interval form estrus day to device placement did not influence positively these assessments (p>0.05). The uterus classified as normal in protocol 4 showed the best percentages of recovering and pregnancy rates (p<0.05) compared to the values of other protocols. However, comparing all protocols, the uterus classified as flaccid showed better recovery responses and classification did not influence uterine pregnancy rate. As the ovarian activity, the presence of corpus luteum influenced recipients recovery rates (p<0.05), whereas the follicles presence only interfered with the pregnancy rate of protocol 4 animals (p<0.05). The number of uses of the device did not influence the recipients recovery pregnancy rates (p>0.05). The reproductive status and protocol number in the history did not affect the recipients recovery rate (p>0.05). However, recipients who did not received PGF2&#945; before intravaginal device placing, had better results than those who received (p<0.05). The recipients which were transferred with expanded blastocyst had better pregnancy rates than they which were transferred with blastocyst (p<0.05). No differences were found in the cow and heifer categories in recipient donor estrus synchrony in relation to pregnancy rate (p>0.05). No influence of the time trial on the pregnancy rate (p>0.05). The protocols which employed PGF2&#945; 48 hours before the withdrawal had better recipients recovery rates than the protocols that applications were made on intravaginal device removal (p<0.05). Protocol 4 recipients had higher pregnancy rates, although it was a group of low numbers of animals. The used protocols interfered with the recipients recovery rate, and the applications of PGF2&#945; 48 hours before intravaginal device removal, resulted in improved estrus synchronization responses, so the answer was more pronounced when females were cyclical in occasion of the beginning of synchronization; intervals from the last estrus to intravaginal device placement over 90 days (anestrus) influence negatively the responses to estrus and ovulation synchronization protocols. However, the classes of interval from estrus to intravaginal device placement (CLAPROT), the covariates showed no marked effect on the recipients recovery response; The female categories (cows and heifers) did not influence the responses to estrus synchronization treatments, although heifers in the pre-puberty are less responsive to PGF2&#945; application in the beginning of the protocol. Regardless of the females category, the presence of the corpus luteum and flaccid uterine tone at the time of intravaginal device placement proved to be positively related to the recipients recovery response; Reusing intravaginal device has no influence on the recovery and pregnancy rates in embryo recipients; Females with histories of prior use of synchronization protocols with the use of PGF2&#945; become less responsive to new synchronization protocols, while not presenting the same behavior with respect to protocols with progesterone associated with PGF2&#945;.